Redx Pharma has filed a patent for compounds that inhibit the Wnt signaling pathway, specifically targeting Porcupine. The invention includes processes for preparing the compounds and their use in treating various cancers and enhancing anti-cancer treatments. GlobalData’s report on Redx Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Redx Pharma Plc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Redx Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Redx Pharma's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

The filed patent (Publication Number: US20230365549A1) includes claims related to a compound, pharmaceutical compositions containing the compound, and methods of treating various conditions in subjects. The compound mentioned in the claims is intended for use in treating conditions such as cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia. The pharmaceutical compositions described in the patent consist of the compound along with pharmaceutically acceptable adjuvants, diluents, or carriers to facilitate administration to subjects in need of treatment.

Furthermore, the patent outlines specific methods for treating conditions in subjects by administering a therapeutically effective amount of the compound mentioned in the claims. The conditions targeted for treatment include esophageal squamous cell carcinoma, gastric cancer, glioblastomas, astrocytomas, retinoblastoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rabdomysarcoma, Wilm's tumor, basal cell carcinoma, non-small cell lung cancer, brain tumor, hormone refractory prostate cancer, prostate cancer, metastatic breast cancer, breast cancer, metastatic pancreatic cancer, pancreatic cancer, colorectal cancer, cervical cancer, head and neck squamous cell carcinoma, and cancer of the head and neck. These methods involve the administration of the compound along with appropriate adjuvants, diluents, or carriers to ensure effective treatment of the specified conditions in subjects requiring medical intervention.

To know more about GlobalData’s detailed insights on Redx Pharma, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies